The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Adenosine Deaminase, Nitric Oxide, Superoxide Dismutase, and Xanthine Oxidase in Patients with Major Depression: Impact of Antidepressant Treatment
Abstract
Background There has been much evidence in recent years that free oxygen radicals and nitric oxide (NO) may play an important role in the pathophysiology of neuropsychiatric disorders. In this study, we aimed to investigate whether NO, xanthine oxidase (XO), superoxide dismutase (SOD), and adenosine deaminase (ADA) levels are associated with major depression (MD) and to evaluate the impact of antidepressant treatments on NO, SOD, ADA and XO levels in MD.Methods Thirty-six patients who were diagnosed as MD according to DSM-IV criteria and 20 healthy controls were included. The serum levels of NO, XO, SOD, and ADA were measured by spectrophotometric methods both in patients and controls. Patients were treated with antidepressant drugs for 8 weeks. All patients were assessed by Hamilton Depression Rating Scale (HDRS) both before and after antidepressant treatment.Results ADA and XO levels of the patients were significantly higher than the controls. SOD level of the patients was significantly lower than the controls. Although NO levels of the patients were higher than the controls, the difference was not statistically significant. There was no correlation between HDRS and the parameters studied (SOD, ADA, XO, and NO) of the patients. After 8 weeks of antidepressant treatment, ADA and SOD activities were increased, whereas NO and, XO levels decreased significantly.Conclusions ADA, XO, and SOD activity may have a pathophysiological role in MD and may predict prognosis of MD. Activity of these enzymes may be used to monitor effects of the antidepressant treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increased oxidative stress markers and neuroinflammation have been reported in the blood of depressed patients [56]”
From Oxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant Approaches (2016) · cites this paper as [56]
In the citing paper
“increased serum XO levels observed in MDD subjects suggest increased systemic ROS production [29].”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [29]
In the citing paper
“suggesting that normalization of these enzymes was associated with symptomatic improvement [29].”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [29]
In the citing paper
“Treatment with citalopram (20 mg/day, n = 10), fluoxetine (20 mg/day, n = 11), fluvoxamine (150 mg/day, n = 7), or sertraline (50 mg/day, n = 8) for 8 weeks increased SOD activity whereas decreased XO levels”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [29]
In the citing paper
“Also, the authors did not find a significant relationship between the duration of illness and SOD, XO activities, or nitrite levels in this cohort.”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [29]
In the citing paper
“Decreased serum SOD and increased XO were found in 20 individuals with MDD (age range 17–62 years, 19/17 F/M ratio) [29].”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [29]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 20,078
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,786
A simple method for clinical assay of superoxide dismutase.
Sun, Y., Oberley, L. W., & Li, Y. (1988) · Clinical Chemistry · doi:10.1093/clinchem/34.3.497 · Cited by 4,537
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115
Lipid peroxidation and antioxidants as biomarkers of tissue damage
Gutteridge, J. M. C. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.12.1819 · Cited by 1,849
Murray, R. K. (1998) · Medical Entomology and Zoology · Cited by 905
Determination of Inorganic Nitrate in Serum and Urine by a Kinetic Cadmium-Reduction Method
Cortas, N. K., & Wakid, N. W. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.8.1440 · Cited by 894
Bilici, M., Efe, H., Köroğlu, M. A., Uydu, H. A., Bekaroğlu, M., & Değer, O. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00199-3 · Cited by 718
Durak, İ., Yurtarslanl, Z., Canbolat, O., & Akyol, Ö. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90307-p · Cited by 388
Free radical pathology and antioxidant defense in schizophrenia: a review
Mahadik, S. P., & Mukherjee, S. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00049-6 · Cited by 329
Fenton, W. S., Hibbeln, J. R., & Knable, M. B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00092-x · Cited by 328
Malignant transformation‐linked imbalance: Decreased xanthine oxidase activity in hepatomas
Prajda, N., & Weber, G. F. (1975) · FEBS Letters · doi:10.1016/0014-5793(75)80385-1 · Cited by 315
Akyol, Ö., Herken, H., Uz, E., Fadıllıoğlu, E., Ünal, S., Söğüt, S., Özyurt, H., & SAVAS, H. A. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00220-8 · Cited by 280
Self-citationHerken, H., Uz, E., Özyurt, H., Söğüt, S., Vırıt, O., & Akyol, Ö. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000789 · Cited by 238
Self-citationBrain circuits in panic disorder
Coplan, J. D., & Lydiard, R. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00300-x · Cited by 195
Kuloğlu, M., Atmaca, M., Tezcan, E., Geçici, Ö., Tunckol, H., & Üstündağ, B. (2002) · Neuropsychobiology · doi:10.1159/000063573 · Cited by 178
Peet, M., Laugharne, J. D. E., Mellor, J. E., & Ramchand, C. N. (1996) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90148-9 · Cited by 170
Xanthine oxidase from human liver: Purification and characterization
Krenitsky, T. A., Spector, T., & Hall, W. W. (1986) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(86)90539-4 · Cited by 138
Antioxidant Enzyme and Malondialdehyde Levels in Patients with Panic Disorder
Kuloğlu, M., Atmaca, M., Tezcan, E., Üstündağ, B., & Bulut, S. (2002) · Neuropsychobiology · doi:10.1159/000067810 · Cited by 137
Possible Role of Nitric Oxide and Adrenomedullin in Bipolar Affective Disorder
SAVAS, H. A., Herken, H., Yürekli, M., Uz, E., Tutkun, H., Zoroğlu, S. S., Özen, M. E., Cengiz, B., & Akyol, Ö. (2002) · Neuropsychobiology · doi:10.1159/000048677 · Cited by 111
Self-citationPhospholipid Spectrum Disorder in Psychiatry
Healy, D. (1999) · Journal of the Royal Society of Medicine · doi:10.1177/014107689909201216 · Cited by 109
Corrigan, F. M. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.2.191-a · Cited by 108
Koltuksuz, U., Irmak, M. K., Karaman, A., Uz, E., Var, A., Özyurt, H., & Akyol, Ö. (2000) · Urological Research · doi:10.1007/s002400000145 · Cited by 99
Chrapko, W. E., Jurasz, P., Radomski, M. W., Archer, S. L., Newman, S. C., Baker, G. B., Lara, N., & Mellédo, J. L. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300961 · Cited by 97
Increased Lymphocyte Adenosine Deaminase in Typhoid Fever
Galanti, B., Nardiello, S., Russo, M., & Fiorentino, F. (1981) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365548.1981.11690366 · Cited by 86
Srivastava, N., Barthwal, M. K., Dalal, P., Agarwal, A., Nag, D., Seth, P. K., Srimal, R. C., & Dikshit, M. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00421-9 · Cited by 80
Herken, H., Akyol, Ö., Yılmaz, H. R., Tutkun, H., SAVAS, H. A., Özen, M. E., Kalenderoğlu, A., & Güleç, M. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.742 · Cited by 69
Self-citationThe possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia
Zoroğlu, S. S., Herken, H., Yürekli, M., Uz, E., Tutkun, H., SAVAS, H. A., Bağcı, C., Özen, M. E., Cengiz, B., Çakmak, E. A., et al. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00014-6 · Cited by 67
Self-citationDipeptidyl peptidase IV and adenosine deaminase activity
Elgün, S., Keskinege, A., & Kumbasar, H. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00039-6 · Cited by 62
Yu, Y. W. ‐., Chen, T., Wang, Y.-C., Liou, Y., Hong, C., & Tsai, S. (2003) · Neuropsychobiology · doi:10.1159/000070582 · Cited by 54
Nitric oxide: a spatial second messenger
Schulman, H. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000197 · Cited by 51
Monoamine oxidase and cortisol response in depression and schizophrenia
Pandey, G. N., Sharma, R. P., Janicak, P. G., & Davis, J. M. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90064-a · Cited by 35
Papageorgiou, C., Grapsa, E. J., Christodoulou, G. N., Zerefos, N., Stamatelopoulos, S. F., & Christodoulou, G. N. (2001) · Psychotherapy and Psychosomatics · doi:10.1159/000056256 · Cited by 30
On the of Monoamine Oxidase, the Emotions, and Adaptation to Stress
Richardson, J. S. (1993) · International Journal of Neuroscience · doi:10.3109/00207459309000563 · Cited by 27
Deliconstantinos, G., & Villiotou, V. (1996) · Neurochemical Research · doi:10.1007/bf02527672 · Cited by 23
Şar, V. (1998) · Cited by 19
Akyol, Ö., Gökbulut, İ., Köksal, N., Akın, H., Özyurt, H., & Yıldırım, Z. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00203-x · Cited by 18
Research works printed but not linked: 1
- Gutteridge, 1995, Lipid peroxidation and antioxidants as biomarkers of tissue damage, Clin Chem, 41, 1819, 10.1093/clinchem/41.12.1819 · DOI
Cited by
Sorted by citations
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Leonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.014 · Cited by 724
Metadata
- Authors
- Herken, H., Gurel, A., Selek, S., Armutcu, F., Ozen, M. E., Bulut, M., Kap, O., Yumru, M., Savas, H. A., & Akyol, O.
- Affiliations
- Pamukkale University (TR)
- Gaziantep University (TR)
- Venue
- Archives of Medical Research
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 38
- Issue
- 2
- Pages
- 247-252
- ISSN
- 0066-6769 (ISSN-L)
- 0188-4409
- OpenAlex
- W2069692485
- Cited by
- 322
- References
- 39
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 11 · 2023: 17 · 2022: 22 · 2021: 18 · 2020: 23 · 2019: 15 · 2018: 17 · 2017: 17 · 2016: 21 · 2015: 23 · 2014: 25 · 2013: 23 · 2012: 21
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Medical Research (publishedVersion)
- PubMed (publishedVersion)
- Zonguldak Bülent Ecevit University Institutional Repository (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- major depressive disorder, adenosine deaminase, nitric oxide, superoxide dismutase, xanthine oxidase, antidepressant treatment, oxidative stress, oxygen free radicals, depression pathophysiology, treatment response monitoring
- MeSH terms
- Adenosine Deaminase, Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Nitric Oxide, Prognosis, Superoxide Dismutase, Xanthine Oxidase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
